Next Article in Journal
Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo
Next Article in Special Issue
Molecular Mechanisms of Sensorineural Hearing Loss and Development of Inner Ear Therapeutics
Previous Article in Journal
Potential Enhancement of Metformin Hydrochloride in Lipid Vesicles Targeting Therapeutic Efficacy in Diabetic Treatment
Previous Article in Special Issue
Activation of KCNQ4 as a Therapeutic Strategy to Treat Hearing Loss
Article

Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice

1
Department of Pharmacology and Pharmacotherapy, Semmelweis University, H-1089 Budapest, Hungary
2
Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, H-1083 Budapest, Hungary
3
Department of Pharmacodynamics, Semmelweis University, H-1089 Budapest, Hungary
4
Department of Oral Biology, Semmelweis University, H-1089 Budapest, Hungary
5
Laboratory of Molecular Pharmacology, Institute of Experimental Medicine, H-1083 Budapest, Hungary
*
Author to whom correspondence should be addressed.
Academic Editor: Srdjan M. Vlajkovic
Int. J. Mol. Sci. 2021, 22(6), 2853; https://doi.org/10.3390/ijms22062853
Received: 25 January 2021 / Revised: 5 March 2021 / Accepted: 9 March 2021 / Published: 11 March 2021
Age-related hearing loss (ARHL), a sensorineural hearing loss of multifactorial origin, increases its prevalence in aging societies. Besides hearing aids and cochlear implants, there is no FDA approved efficient pharmacotherapy to either cure or prevent ARHL. We hypothesized that selegiline, an antiparkinsonian drug, could be a promising candidate for the treatment due to its complex neuroprotective, antioxidant, antiapoptotic, and dopaminergic neurotransmission enhancing effects. We monitored by repeated Auditory Brainstem Response (ABR) measurements the effect of chronic per os selegiline administration on the hearing function in BALB/c and DBA/2J mice, which strains exhibit moderate and rapid progressive high frequency hearing loss, respectively. The treatments were started at 1 month of age and lasted until almost a year and 5 months of age, respectively. In BALB/c mice, 4 mg/kg selegiline significantly mitigated the progression of ARHL at higher frequencies. Used in a wide dose range (0.15–45 mg/kg), selegiline had no effect in DBA/2J mice. Our results suggest that selegiline can partially preserve the hearing in certain forms of ARHL by alleviating its development. It might also be otoprotective in other mammals or humans. View Full-Text
Keywords: age-related hearing loss; selegiline; chronic oral treatment; hearing protection; mouse model age-related hearing loss; selegiline; chronic oral treatment; hearing protection; mouse model
Show Figures

Figure 1

MDPI and ACS Style

Szepesy, J.; Humli, V.; Farkas, J.; Miklya, I.; Tímár, J.; Tábi, T.; Gáborján, A.; Polony, G.; Szirmai, Á.; Tamás, L.; Köles, L.; Vizi, E.S.; Zelles, T. Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice. Int. J. Mol. Sci. 2021, 22, 2853. https://doi.org/10.3390/ijms22062853

AMA Style

Szepesy J, Humli V, Farkas J, Miklya I, Tímár J, Tábi T, Gáborján A, Polony G, Szirmai Á, Tamás L, Köles L, Vizi ES, Zelles T. Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice. International Journal of Molecular Sciences. 2021; 22(6):2853. https://doi.org/10.3390/ijms22062853

Chicago/Turabian Style

Szepesy, Judit, Viktória Humli, János Farkas, Ildikó Miklya, Júlia Tímár, Tamás Tábi, Anita Gáborján, Gábor Polony, Ágnes Szirmai, László Tamás, László Köles, Elek S. Vizi, and Tibor Zelles. 2021. "Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice" International Journal of Molecular Sciences 22, no. 6: 2853. https://doi.org/10.3390/ijms22062853

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop